Related Experiment Videos
[Bone marrow transplantation. Indications, chances and perspectives]
1Abteilung Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule Hannover. Hertenstein.Bernd@mh-hannover.de
Der Internist
|October 27, 2004
Summary
Hematopoietic stem cell transplantation is crucial for treating various blood cancers and anemias. Advances now allow transplantation in older patients, improving outcomes for leukemia, lymphoma, and myeloma.
Area of Science:
- Hematology
- Oncology
- Immunogenetics
Context:
- Hematopoietic stem cell transplantation (HSCT) is a cornerstone in treating hematologic malignancies and anemias.
- Conditions treated include leukemias, myelodysplastic syndromes, lymphomas, multiple myeloma, and aplastic anemia.
Purpose:
- To outline the indications and evolving criteria for HSCT.
- To highlight the impact of recent advancements on patient eligibility and treatment outcomes.
Summary:
- HSCT is vital for acute/chronic leukemias, myelodysplastic syndromes, lymphomas, multiple myeloma, and aplastic anemia.
- Transplant decisions involve disease stage, risk factors, and patient age, requiring expert hematologist/oncologist input.
- Immunogenetic advances enhance unrelated donor transplants; improved supportive care and conditioning regimens extend eligibility to 60-65 years for allogeneic and older for autologous HSCT.
Impact:
- Expanded eligibility for HSCT in older adults.
- Improved treatment results through immunogenetic advancements and better supportive care.
- Increased application of HSCT for a wider range of hematologic disorders.